Skip to content

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Outcame of Cases With Hemolytic Uremic Syndrome Attending Assiut University Child Hospital

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03690024
Enrollment
50
Registered
2018-10-01
Start date
2018-10-01
Completion date
2019-12-01
Last updated
2018-10-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemolytic Uremic Syndrome of Childhood

Brief summary

Diarrhea-associated hemolytic uremic syndrome (D+HUS) is defined as a prodrome of enteritis followed by thrombocytopenia (\< 150,000/mm3), microangiopathic hemolytic anemia, and signs of variable degrees of renal damage (increase in serum Cr, proteinuria, and/or hematuria) . Our aim is to detect the most reliable early predictors of poor prognosis to identify children at major risk of bad outcome who could eventually benefit from early specific treatments.

Detailed description

The disease is caused predominantly by Shiga toxin-producing enterohemorrhagic Escherichia coli (STEC) and is one of the most common etiologies of acute kidney injury (AKI) and an important cause of acquired chronic kidney disease in children \[2\]. The incidence of HUC tends to parallel the seasonal fluctuation of E.coli o175 : H7 infection which peaks between June & September. Nowadays, the incidence increases and is typically observe in infants and children, especially those aged 6 months to 4 years. A complicated disease course is defined as the development of one or more of the following manifestations: neurological dysfunction, severe bowel injury, pancreatitis, hemodynamic instability (symptomatic hypotension, multi-organ failure), cardiac (congestive heart failure, myocarditis, pericarditis, arrhythmia) or pulmonary involvement (pulmonary edema, acute respiratory distress syndrome), hematologic complications (hemorrhage), and death \[1\]. Many laboratory and clinical markers upon admission have been associated to severe forms of the disease, including high initial leukocyte and hematocrit levels, major extrarenal complications, dehydration and recently, the blood urea nitrogen (BUN) to serum creatinine (Cr) ratio \[1\], \[4-6\]. Treatment of D+HUS remains supportive; thus, early identification of high-risk patients can optimize their management \[1-3\].

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
No minimum to 18 Years
Healthy volunteers
No

Inclusion criteria

* all patients less than 18 years diagnosed with Hemolytic Uremic Syndrome

Design outcomes

Primary

MeasureTime frameDescription
Complete remission1 yearNumber of cases that treated and discharged from hospital
Death1 yearNumber of cases that ended by death
Residual renal affection1 yearNumber of cases with residual raised renal chemistry

Contacts

Primary ContactFahim Mohamed Fahim, Professor
fahim.osman@med.au.edu.eg01002500073
Backup ContactAhlam Badawy Ali Badawy, Ph.D.
drahlamali@aun.edu.eg01006807866

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026